INTRODUCTION
M ULTIPLE SCLEROSIS (MS) is an inflammatory disease of the human CNS resulting in demyelination and associated irreversible tissue injury. It represents the most significant primary neurological cause of disability among young adults in the United States. 1 Studies of the animal model of MS, experimental autoimmune encephalomyelitis (EAE), support the theory that myelin-specific CD4+ T cells that have been activated in the periphery and produce proinflammatory (Th1) cytokines are the major mediators of MS. 2, 3 EAE is primarily induced in animals by generating T cell responses to myelin proteins such as myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte glycoprotein (MOG) through immunization with these proteins or peptides thereof. 4 We have previously established a novel mouse model for MS by generating mice that are transgenic for the 5B6 T-cell receptor (TCR), which specifically recognizes myelin PLP139-151. 5 Spleen cells from 5B6 transgenic mice predominantly harbor CD4+ T cells, which express almost exclusively the 5B6 TCR and specifically respond to stimulation with PLP139-151 by proliferation and production of proinflammatory cytokines such as interleukin (IL)-2 and interferon (INF)-γ in vitro. Furthermore, within 6 mo of age, 40% of 5B6 transgenic SJL mice spontaneously developed EAE, which shares many pathological features with MS. Consistent with a critical function in the pathogenesis of spontaneous EAE, PLP-specific T cells could readily be detected in CNS sections of diseased but not healthy 5B6 transgenic mice by immunohistochemistry.
The critical role of the immune system in the pathogenesis of MS has had important therapeutic implications, which led to therapies with general immunosuppressive agents and, more recently, immunomodulatory agents. 6, 7 However, approved drugs for MS have to be frequently injected and are only moderately effective. Thus, there is great need for more efficacious MS therapeutics that ideally can be administered orally. Targeting T cells with small molecules that inhibit their inflammatory responses to CNS myelin proteins is a valid therapeutic strategy and would offer clear advantages over current MS therapies. For example, statins that are orally prescribed to lower blood cholesterol levels also inhibit the production of inflammatory cytokines in T cells and are undergoing clinical trials in MS patients. 8, 9 With the aim to identify druglike molecules that inhibit inflammatory responses in myelin-reactive T cells, we developed a high-throughput screening (HTS) assay for PLP-reactive T cells and screened 41,184 chemical compounds, which had been preselected for increased probability of oral bioavailability. Using primary spleen cells from healthy 5B6 transgenic mice, we identified 6 compounds with a molecular weight (MW) <500 that significantly inhibited the proliferation and production of proinflammatory cytokines such as IL-2 and INF-γ in PLP-reactive T cells in vitro.
MATERIALS AND METHODS

Mice
5B6 transgenic mice specific for a TCR recognizing myelin PLP139-151 were generated and bred as previously described. 5 Staining peripheral blood lymphocytes from tail blood with fluorescence-labeled anti-CD4 (RM4-5) and anti-TCR Vβ6 (RR4-7) antibodies (BD Biosciences, San Diego, CA) and subsequent flow-cytometric analysis identified transgenic litters. Healthy 5B6 transgenic female SJL or B10.S mice were used at 4 to 8 wk of age as donors of PLP-reactive T cells from spleens (∼5 × 10 7 cells/spleen). Mice were housed at the Partners Research Building animal facility under specific pathogen-free and viral antibody-free conditions in accordance with the guidelines of Harvard Medical School.
Isolation of splenic T cells
We prepared single T-cell suspension of spleens from 5B6 transgenic mice by gently pressing the spleen with the plunger of a syringe through a cell strainer (BD Falcon, Bedford, MA). Red blood cells were subsequently lysed by incubating the spleen cell suspension in ammonium chloride (0.15 M, pH 7.2) for 5 min on ice (hypotonic shock). The cells were then washed twice in DMEM (Cambrex, Walkersville, MD) and used for HTS and T-cell proliferation assays as described below.
Peptide antigens
The following peptide antigens were used: PLP139-151 (HSLGKWLGHPDKF) and PLP256-266 (TFMIAATYNFA). The peptides were synthesized by Quality Controlled Biochemicals (Hopkinton, MA) and were >90% pure as determined by high-performance liquid chromatography.
Compound library and HTS
The compound library from the Laboratory for Drug Discovery in Neurodegeneration (LDDN) at the Harvard Center for Neurodegeneration and Repair consisted of purchased druglike molecules, which were selected using computational filters to increase the probability of oral bioavailability and blood-brain barrier penetration. These filters were based on polar surface area, which has been demonstrated to correlate strongly with human intestinal absorption, Caco-2 monolayer permeability, and blood-brain barrier penetration. 10 The filters also included other critical parameters such as the rules of Lipinski, 11 solubility, and the lack of reactive functionalities. Several potent leads for medicinal chemistry have previously been identified for different projects from screens of this library. [12] [13] [14] [15] Compounds (MW = 350-550) were prespotted in 0.3 µl DMSO (Sigma-Aldrich, St. Louis, MO; ∼1.7 mM) on 384-well plates, which also contained wells with only DMSO as vehicle controls. DMEM (90 µl/well) was added to defrosted compound plates using a dispenser unit. Diluted compounds and vehicle controls (10 µl/well) were subsequently transferred to Nalgene Nunc (Rochester, NY) 384-well white assay plates using a Biomek unit (Beckman Coulter, Fullerton, CA). Aliquots (40 µl/well) of spleen cell suspension (1 × 10 6 cells/ml) in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 10 mM HEPES, and 50 µM mercaptoethanaol (Sigma-Aldrich, St. Louis, MO; referred to as DMEM complete) containing PLP139-151 (12.5 µg/ml) or medium only as controls were added to the assay plates using a Multidrop 384-well cell dispenser (Thermo LabSystems, Franklin, MA). The average final concentration of the screened compounds was 1 µM, and the percentage of DMSO was 0.07%. The HTS plates were briefly shaken and incubated in a humidified incubator with 5% CO 2 at 37 °C for 65 h. Following incubation, the assay plates were left at room temperature for 20 min before 40 µl Cell Titre-Glo (Promega, Madison, WI) was added to each well using a Biomek unit. The plates were shaken for 1 to 2 min and incubated for 10 min at room temperature, and the luminescence was determined using an LJL analyst (Molecular Devices, Sunnyvale, CA). The inhibition of T-cell proliferation was calculated from the measured mean luminescence using the following formula: % inhibition = 100 × [1 -(sample -negative control)/(positive control -negative control)], where negative control designates the wells with medium and vehicle (DMSO) only (n = 16) and positive control refers to wells with PLP139-151 in medium with vehicle (DMSO; n = 16).
To assess the quality of the HTS, we determined the Z′ factor for each assay plate using the following formula 16 : Z′ = 1 -[(3 SD positive control + 3 SD negative control)/(positive control -negative control)], where SD refers to the standard deviation of mean positive and negative controls as indicated above. Analysis of the data was done using Excel software.
Cytotoxicity assay
We assessed the potential toxicity of the compounds on Jurkat T cells using the CytoTox-One assay (Promega) according to the manufacturer's instructions with the following modifications. Diluted compounds or DMSO for vehicle controls (10 µl) were transferred to triplicate wells of Nunc 384-well white assay plates containing Jurkat T cells (7.5 × 10 5 cells/ml) in 40 µl RPMI (Cambrex, Walkersville, MD) supplemented with 10% heatinactivated FCS (Sigma-Aldrich), 2 mM L-glutamine, and 10 mM HEPES (both from Bio-Whittaker, Walkersville, MD). The average final concentration of the screened compounds was 1 µM, and the percentage of DMSO was 0.05%. The plates were sealed with gas-permeable membranes (Bellco Glass, Vineland, NJ) and incubated in a humidified incubator with 5% CO 2 at 37 °C for 65 h. CytoTox-One lysis buffer was subsequently added to half of the vehicle control wells, and the plates were left at room temperature for 30 min to lyse the cells. Subsequently, 15 µl of supernatant of each well was replaced by 30 µl/well CytoTox reagent. Following incubation at room temperature for 10 min, CytoTox-Stop solution (15 µl/well) was added to the plates. Fluorescence was read using a Gemini plate reader (Molecular Devices) with an excitation at 560 nm and emission at 590 nm wavelength. Cytoxicity (%) of the compounds in Jurkat T cells was calculated using the following formula: % cytotoxicity = 100 × [(sample -medium control)/(lysis control -medium control)], where medium control and lysis control refer to the mean fluorescence values detected in the wells with vehicle (DMSO) and lysed cells, respectively.
The potential cytotoxicity of compounds was also determined by standard trypan blue exclusion assay following the exposure of mouse spleen cells to selected compounds (10 µM) in DMEM complete. The unstained and total number of cells was counted using a hemocytometer.
(3H) thymidine uptake assay
Concentration-dependent activity of selected compounds on T-cell proliferation was determined by (3H) thymidine uptake assay in PLP-stimulated T cells from 5B6 transgenic mice. We prepared a single-cell suspension of spleens from these mice and lysed the red blood cells by hypotonic shock as described above. Selected compounds were serially diluted in DMSO at indicated concentrations and transferred in triplicates of 96well, round-bottom plates. Spleen cells (9 × 10 4 cell/well) and PLP139-151 (10 µg/ml, final concentration) in DMEM complete were subsequently added to each well, and the cultures were incubated in a humidified incubator with 5% CO 2 at 37 °C for 48 h. Subsequently, 1 µCi of [ 3 H] thymidine (Perkin Elmer, Wellesley, MA) was added to each well for an additional 12 h of culture. Cells were aspirated on filter mats (Perkin Elmer), which were subsequently washed with ∼0.8 ml/well distilled water 4 times using a Harvester 96 (Tomtec, Orange, CT). Finally, the filter mats were dried and sealed in plastic sample bags, each containing 10 ml scintillation liquid (Perkin Elmer). Proliferation of T cells was assessed by determining the incorporated thymidine in counts per minute on a Beta-liquid scintillation counter (Wallac, Turku, Finland). The assay was repeated 3 times with newly purchased compounds for candidates that demonstrated concentration-dependent inhibition of T-cell proliferation.
Enzyme-linked immunosorbent assay
The concentration of IL-2 and INF-γ in supernatants of PLP-stimulated splenic T-cell cultures in the presence of newly purchased stocks of selected compounds at different concentrations was determined after 40 h by quantitative capture enzymelinked immunosorbent assay (ELISA) using OptEl systems (BD Biosciences) according to the manufacturer's instructions. Assays were developed with TMB Microwell Peroxidase Substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD) and read at 450 nm.
RESULTS
Design of cell-based HTS assay and optimization
To identify compounds that inhibit the proliferation of PLPreactive T cells, we used primary splenic T cells from mice that are transgenic for the 5B6 T cell receptor, which specifically recognizes myelin PLP139-151. More than 95% of CD4+ T cells in the spleen of 5B6 transgenic mice express the transgenic TCR Vβ6 and proliferate vigorously in response to stimulation with PLP139-151 but not to the control peptide PLP256-266 ( Fig. 1A) . 5 PLP139-151-specific stimulation of transgenic T cells also resulted in significant secretion of the proinflammatory cytokines IL-2 and INF-γ, which are important for the pathological function of myelin-specific T cells ( Fig. 1B) . 4 In contrast, spleen cells from 5B6 transgenic mice stimulated with the control peptide PLP256-266 failed to secrete significant amounts of IL-2 and INF-γ ( Fig. 1B) . Thus, stimulation of spleen cells from the 5B6 transgenic mice with PLP139-151 resulted in inflammatory T-cell responses that were specific to stimulation with PLP139-151.
To determine the inhibitory activity of compounds on the proliferation of PLP-reactive T cells in an HTS format, we used a commercially available assay that measures the number of viable cells based on the amount of adenosine triphosphate (ATP) present in the culture determined by luciferase luminescence. Because the amount of ATP is directly proportional to the number of cells in the culture, the assay allowed assessing the effect of compounds on the proliferation of PLP-stimulated T cells. Thus, the inhibitory effect of compounds on T-cell proliferation was determined relative to control samples containing medium with vehicle (DMSO) in presence (positive control) or absence (negative control) of PLP139-151.
Identifying Druglike Inhibitors of Myelin-Reactive T Cells
One of the main challenges encountered while developing the bioluminescent HTS assay was the relative high level of background signal when using low numbers of primary spleen cells. To solve this challenge, we tested increasing densities of cells per well until we observed strong specific signals over minimal background luminescence. The optimal density of spleen cells was determined to be 40,000 cells/well in white 384-well plates, which yielded specific signals that were typically 3-fold higher than signals from nonstimulated controls. We minimized the number of false-positive hits that could occur because of compound toxicity by screening the compound library at an average final concentration of 1 µM. Inhibitory compounds that did not show significant T-cell cytotoxicity were subsequently tested for concentration-dependent inhibitory activity of proliferation in T cells from 5B6 transgenic mice by tritiated thymidine uptake assay in 96-well plates. To determine whether the selected compounds also inhibited the secretion of proinflammatory cytokines in T cells, we measured the concentration of IL-2 and INF-γ in the supernatants of the PLP-stimulated T-cell cultures by ELISA (see below).
Identification of inhibitors of PLP-specific T-cell proliferation by HTS
To identify compounds that inhibited proliferation in PLPreactive T cells, we screened a total of 41,184 compounds from the LDDN library in a high-throughput format. Compounds in this library were selected for their druglike properties including oral bioavailability and passage through the blood-brain barrier. We determined the inhibitory activity of the compounds on the proliferation of PLP139-151-stimulated T cells from 5B6 transgenic mice at 1 µM by measuring the number of metabolically active cells after 65 h of culture by a luciferase luminescence assay.
To isolate potent inhibitors, we selected 302 primary hit compounds (0.7% of compounds screened) that demonstrated >50% inhibitory activity relative to vehicle controls for further analysis ( Fig. 2A) . Compounds that did not inhibit but promoted the proliferation of 5B6 transgenic T cells in response to PLP139-151 stimulation (represented by negative values in Fig. 2A) were not analyzed further. To exclude toxic compounds, we assayed the selected compounds for their potential cytotoxic effects. Thus, we incubated Jurkat T cells in the presence of the compounds (1 µM) and determined the amount of lactate dehyrogenase released from cells with damaged cell membranes after 65 h. In addition, we also determined the viability of mouse spleen cells following compound exposure using the standard trypan blue exclusion assay. As we were interested in compounds that did not show significant T-cell cytotoxicity, we selected those that demonstrated <5% cytotoxicity relative to controls samples. Of the 302 primary hits, 239 compounds demonstrated <5% T-cell cytotoxicity, whereas 63 compounds showed higher cytotoxicity and thus were excluded from further analysis (data not shown). To this end, we identified 239 compounds (∼0.6% of compounds screened) that inhibited proliferation in PLP-reactive T cells by >50% and did not demonstrate significant cytotoxic effects in T cells.
It was previously reported that the edge effect significantly contributes to the variability of cell-based HTS assays and thereby reduces their performance. 17 To decrease assay variability due to the edge effect, we did not use the peripheral wells of the plates and sealed the culture plates with a gaspermeable membrane during the incubation period. This procedure was effective because the edge effect was minimal in our assay (data not shown). The quality of an HTS assay is generally assessed by its Z′ factor, which defines the dynamic signal range and the data variation for the assay and ranges from 0.5 to 1 for robust and reproducible assays. 16 Consistent with a high-assay quality, the Z′ factors of our assay plates were typically ≥0.5 (Fig. 2B) . The screen was repeated for plates that did not reach a Z′ factor of at least 0.5.
Selected compounds show concentration-dependent inhibition of proliferation in PLP-reactive T cells
To determine the concentration-dependent effect of the 239 selected compounds, we measured their inhibitory activity on the proliferation of PLP-reactive T cells in the presence of different compound concentrations by (3H) thymidine uptake assay in 96-well plates. Thus, we stimulated spleen cells from 5B6 transgenic mice with PLP139-151 (10 µg/ml) in the presence of different concentrations of compounds (0-10 µM) for 60 h, which included an overnight pulse with (3H) thymidine (1 µCi/well). The inhibition of T-cell proliferation by the examined compounds was determined relative to that in wells containing medium with vehicle control (DMSO).
Three compounds (102, 113, 117) inhibited T-cell proliferation with increasing compound concentration at 4 to 5 different concentrations examined. Three other compounds (118, 144, 163) showed increasing inhibitory effects on T-cell proliferation at the 3 highest concentrations examined (0.1, 1, and 10 µM), indicating that their concentration-dependent activity at the concentrations examined was more restricted compared to the compounds above ( Fig. 3) . Remarkably, 5 of the 6 selected compounds (102, 113, 117, 118, and 163) attenuated the proliferation of PLPstimulated T cells by ≥80% compared to vehicle controls at the highest concentration (10 µM). Further analysis of these compounds determined that each had a tractable structure and a molecular weight <500. We subsequently confirmed the identity and concentration-dependent inhibitory activity of these compounds in PLP-specific T-cell proliferation assays by testing aliquots from freshly purchased compounds. The remaining 233 compounds either confirmed their inhibitory effects but failed to demonstrate concentration-dependent inhibition of T-cell proliferation over at least 3 different compound concentrations (220 compounds) or did not confirm the inhibitory activity seen in the primary screen (13 compounds; data not shown).
Taken together, we identified 6 compounds (∼0.015% of all screened compounds) that significantly inhibited the proliferation of PLP-reactive T cells in a concentration-dependent fashion compared to vehicle controls (Fig. 3) .
Selected compounds inhibit the secretion of proinflammatory cytokines in PLP-reactive T cells
Stimulation of 5B6 transgenic T cells with PLP139-151 but not PLP256-266 induces their secretion of the proinflammatory cytokines IL-2 and INF-γ ( Fig. 1B) . Studies in EAE have demonstrated that the production of proinflammatory cytokines including IL-2 and INF-γ by myelin-specific T cells are critical for its pathogenesis. 4 To examine whether the selected compounds inhibited the secretion of proinflammatory T-cell cytokines in PLPreactive T cells, we determined the concentration of IL-2 and INF-γ in supernatants of PLP-stimulated T-cell cultures in the presence of these compounds. Thus, spleen cells from 5B6 transgenic mice were stimulated with PLP139-151 in the presence of selected inhibitors as described above, and the culture supernatants were assayed for IL-2 and INF-γ concentrations after 40 h by ELISA.
Five compounds (102, 117, 118, 144, and 163) increasingly inhibited IL-2 secretion in PLP-stimulated T cells at 3 or more increasing compound concentrations compared to controls (Fig. 4A) . Notably, 4 of these compounds had the capacity to completely (∼100%) block the secretion of IL-2 at the highest compound concentration (10 µM). Two compounds (113 and 163) showed weaker inhibitory activity, conferring a maximum of ∼50% to 60% inhibition of IL-2 secretion. Compound 113 demonstrated its highest inhibitory activity at 0.1 µM rather than at 10 µM as the other compounds.
The 6 selected compounds were also potent in inhibiting the secretion of INF-γ secretion in PLP-stimulated T cells because they conferred >80% inhibition at the highest concentrations examined (1 µM, 10 µM; Fig. 4B, and data not shown) . At <1 µM, the inhibitory activity of most compounds was decreased to 10% to 20%, except for 2 compounds (102 and 163), which still inhibited INF-γ secretion by >45% (data not shown). These data indicate that the inhibition of INF-γ secretion by the selected compounds was more effective at higher concentrations (>1 µM) than that of IL-2.
Taken together, the selected compounds demonstrated potent activities to inhibit the secretion of both IL-2 and INF-γ by PLP-stimulated T cells. 
DISCUSSION
Multiple sclerosis is presumed to be an autoimmune disease of the human CNS that is mediated by inflammatory myelinspecific T cells resulting in demyelination and associated irreversible tissue injury. 1, 18 Drugs that have been approved for the treatment of MS are only moderately effective and have to be injected frequently, which carries the risk of generating neutralizing antibodies. 7 Our aim was to identify druglike molecules that inhibit inflammatory responses in PLP-reactive T cells in vitro and thus may serve as valid leads for the development of novel therapeutics for MS.
We developed a cell-based HTS assay for primary T cells from mice transgenic for the myelin PLP-specific TCR 5B6. Splenic T cells from 5B6 transgenic mice respond to stimulation with PLP139-151 specifically by proliferation and secretion of proinflammatory cytokines such as IL-2 and INF-γ in vitro. We screened 41,184 compounds from the LDDN library that had been preselected for increased probability of oral bioavailability for their inhibitory activity on proliferation of PLP139-151-stimulated T cells from 5B6 transgenic mice. To identify compounds with potent inhibitory but minimal cytotoxic effects, we screened the compound library at an average final concentration of 1 µM and selected those compounds that demonstrated >50% inhibitory activity on T-cell proliferation for further analysis. Our HTS assay demonstrated significant robustness and reproducibility, which was indicated by the high Z′ factors (≥0.5) determined in individual assay plates.
Approximately 0.6% of the compounds in the screened library inhibited proliferation in PLP-reactive T cells by >50% at 1 µM relative to vehicle controls. Importantly, the inhibitory activity of these compounds was not due to nonspecific cytotoxic effects because the selected compounds did not demonstrate any significant cytotoxicity in Jurkat T cells and mouse spleen cells. We independently confirmed the inhibitory activity of compounds that were identified in the primary screen by (3H) thymidine uptake assays in 96-well plates with different compound concentrations. These analyses identified 6 compounds that demonstrated concentration-dependent inhibitory activity on Tcell proliferation in response to stimulation with PLP139-151.
The hit rate of our HTS assay, which was relatively low for a cell-based assay, could in part be explained by our decision to screen the compound library at the low compound concentration of 1 µM. This stringent screening condition was chosen to select for potent compounds and to limit the number of false-positive hits, that is, compounds that would inhibit T-cell responses due to cytotoxic effects. Moreover, we selected only compounds that demonstrated concentration-dependent inhibition of T-cell proliferation over at least 3 different concentrations for subsequent analysis. This criterion further decreased the number of hits because most of the compounds that were identified in the HTS did not show the required concentration-dependent inhibition of T-cell proliferation in the secondary assays.
Myelin-reactive T cells that secrete proinflammatory cytokines such as IL-2 and INF-γ have been reported to be critical in the pathogenesis of MS and its animal model EAE. 3, 18 IL-2 is responsible for the progression of T cells from the G1 to S phase of the cell cycle and therefore is a principal T-cell growth factor. 19 INFγ is important in promoting the differentiation of naïve CD4+ T cells to Th1 effector cells. 20 Thus, both proinflammatory cytokines are essential in driving the Th1-mediated inflammation in EAE and MS. The selected compounds markedly inhibited the secretion of both IL-2 and INF-γ in PLP-stimulated T cells compared to the vehicle (DMSO) controls. The compounds' inhibitory effect on IL-2 secretion correlated well with their inhibitory activity on PLP-stimulated T-cell proliferation: Increased inhibition of IL-2 secretion was associated with increased inhibition of T-cell proliferation for 5 of 6 compounds (102, 117, 118, 144, and 163) at higher concentrations (≥1 µM). These findings suggest that the selected compounds may inhibit T-cell proliferation by targeting pathways involved in the production or secretion of IL-2 in T cells. In contrast, a decrease in the inhibition of IL-2 secretion by compound 113 was associated with increased inhibition of T-cell proliferation. These data suggest that compound 113 may target pathways that inhibit T-cell proliferation independently of IL-2. Each selected compound also potently inhibited the secretion of INF-γ in PLP-stimulated T cells at higher concentrations (≥1 µM). At these concentrations, the effect was associated with strong inhibitory activities in T-cell proliferation by compounds 102, 113, and 163, suggesting that the inhibitory effect on INF-γ secretion of these compounds was dependent on inhibition of T-cell proliferation. In contrast, 3 other selected compounds (117, 118, and 144) inhibited INF-γ secretion more potently than T cell proliferation at 1 µM, suggesting that these compounds might affect pathways more directly involved in INF-γ production or secretion.
The exact mechanisms by which our selected compounds exert their anti-inflammatory effect in PLP-reactive T cells remains to be determined. It is conceivable that the compounds may inhibit T cells directly as discussed above (e.g., via IL-2 inhibition); indirectly by affecting antigen-presenting cells such as dendritic cells, which are crucial for effective T-cell responses 21 ; or both. For example, inhibitors of cyclic adenosine monophosphate-specific phophodiesterase (PDE) 4 have been shown to inhibit inflammatory cytokine production and proliferation of T cells directly 22 as well as IL-12 production in dendritic cells. 23 This nonselective immunosuppressive activity is likely responsible for the reported beneficial effects in clinical signs of EAE following administration of rolipram, the prototypic PDE4 inhibitor to mice. 24 In this context, it is interesting to note that most available MS therapies suppress or modulate the immune system in a nonselective fashion and by multiple mechanisms. 25 Thus, based on their anti-inflammatory activity and druglike properties, the 6 compounds identified in our screen may represent valid leads for the development of novel MS therapeutics that could be administered orally.
CONCLUSION
Available MS therapeutics have to be frequently injected and are only moderately effective. Patients would benefit significantly if more efficacious therapeutics that could be administered orally were available. We have developed a T cell-based HTS assay and used it to identify several small molecules (MW <500) that inhibit the proliferation and secretion of proinflammatory cytokines such as IL-2 and INF-γ in myelin PLP-reactive T cells. Thus, our compounds may serve as valid candidates for the development of novel MS therapies that could be administered orally.
